Disease Detail

ID DOID:1520
Name colon carcinoma
Definition A colon cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colon cancer colon carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E RXDX-105 colon carcinoma sensitive detail...
Unknown unknown Bevacizumab + S-49076 colon carcinoma not applicable detail...
MSH6 loss N/A colon carcinoma not applicable detail...
APC inact mut FH535 colon carcinoma sensitive detail...
Unknown unknown BMS-906024 colon carcinoma not applicable detail...
TP53 loss SP600125 colon carcinoma sensitive detail...
Unknown unknown Mps-BAY1 colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2a colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2b colon carcinoma not applicable detail...
Unknown unknown Mps-BAY1 + Paclitaxel colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2a + Paclitaxel colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2b + Paclitaxel colon carcinoma not applicable detail...
TP53 loss MPI-0479605 colon carcinoma sensitive detail...
TP53 wild-type MPI-0479605 colon carcinoma sensitive detail...
TP53 wild-type RB1 wild-type R547 colon carcinoma sensitive detail...
TP53 mutant RB1 wild-type R547 colon carcinoma sensitive detail...
IDH1 R132H Talazoparib colon carcinoma sensitive detail...
IDH1 R132H Olaparib colon carcinoma sensitive detail...
Unknown unknown CFI-402257 + unspecified PD-1 antibody colon carcinoma not applicable detail...
Unknown unknown UD-017 colon carcinoma not applicable detail...
Unknown unknown Hydroxyurea + MU380 colon carcinoma not applicable detail...
Unknown unknown CA-170 colon carcinoma not applicable detail...
TP53 mutant Camptothecin + CHIR-124 colon carcinoma predicted - sensitive detail...
ALK negative CEP-28122 colon carcinoma resistant detail...
Unknown unknown Radiotherapy + XL-844 colon carcinoma not applicable detail...
CTNNB1 S45del NTRC 0066-0 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del Mps-BAY2b colon carcinoma predicted - sensitive detail...
CTNNB1 S45del NMS-P715 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1161909 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1217389 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del Mps1-IN-1 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del MPI-0479605 colon carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01309126 Phase III Cetuximab Cetuximab + PGG beta-glucan Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Terminated
NCT01985763 Phase Ib/II Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Genistein in Treatment of Metastatic Colorectal Cancer Completed
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting